For outpatients with mild-to-moderate COVID-19, inhaled fluticasone furoate does not shorten time to symptom resolution, according to a study published in the Sept. 21 issue of the New England Journal of Medicine.
Sep 21, 2023
0
42
Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized ...
Jul 13, 2023
0
32
Bempedoic acid is associated with a reduction in major adverse cardiovascular events among statin-intolerant primary prevention patients, according to a study published online June 24 in the Journal of the American Medical ...
Jun 26, 2023
0
38
The U.S. Food and Drug Administration approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation.
Jun 15, 2023
0
56
The drug atogepant may help prevent migraines for people who have had no success with other preventive drugs, according to a preliminary study released April 20, 2023, which will be presented at the American Academy of Neurology's ...
Apr 20, 2023
0
53
Guilt is an uncomfortable feeling and can be burdensome. Researchers at the University of Basel have shown that placebos can help reduce feelings of guilt, even when the placebo is administered openly.
Jan 12, 2023
0
64
After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists. ...
Nov 7, 2022
0
32
The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
Sep 7, 2022
0
44
Asthma exacerbations are reduced for children and adolescents with exacerbation-prone eosinophilic asthma who are living in socioeconomically disadvantaged urban neighborhoods and receive mepolizumab therapy, according to ...
Aug 15, 2022
0
83
